37 related articles for article (PubMed ID: 8664919)
1. [T1G3 bladder neoplasms: treatment and results].
Cosciani Cunico S; Magri V; Aulenti V; Tosana M; Botturi A
Arch Ital Urol Androl; 1996 Feb; 68(1):47-50. PubMed ID: 8664921
[TBL] [Abstract][Full Text] [Related]
2. [Conservative treatment of high-risk (T1G3) transitional carcinoma].
Catanzaro F; Torelli F; Catanzaro M; Cappellano F; Pizzoccaro M; Baruffi M; Sironi D; Pozzoli GL
Arch Ital Urol Androl; 1996 Feb; 68(1):21-4. PubMed ID: 8664915
[TBL] [Abstract][Full Text] [Related]
3. T1G3: What to do?
Mandressi A
Arch Ital Urol Androl; 1996 Feb; 68(1):5-7. PubMed ID: 8664922
[No Abstract] [Full Text] [Related]
4. [Transitional carcinoma of the bladder at the T1G3 stage: personal experience].
Roggia A; Pozzi E; Malvestiti GM
Arch Ital Urol Androl; 1996 Feb; 68(1):25-8. PubMed ID: 8664916
[TBL] [Abstract][Full Text] [Related]
5. [T1G3 bladder tumors: our experience].
Pagano S; Franzoso F; Pachera F; Ruggeri P; Sorboli G
Arch Ital Urol Androl; 1996 Feb; 68(1):39-45. PubMed ID: 8664920
[TBL] [Abstract][Full Text] [Related]
6. [T1G3 bladder tumors: 5 years later].
Pegoraro C; Bondovalli C; Dall'Oglio B; Schiavon L; Luciano M; Parma A
Arch Ital Urol Androl; 1996 Feb; 68(1):35-8. PubMed ID: 8664919
[TBL] [Abstract][Full Text] [Related]
7. The optimal management of T1G3 bladder cancer.
Emiliozzi P; Pansadoro A; Pansadoro V
BJU Int; 2008 Nov; 102(9 Pt B):1265-73. PubMed ID: 19035891
[No Abstract] [Full Text] [Related]
8. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
[TBL] [Abstract][Full Text] [Related]
9. [Therapy and follow-up of bladder cancer].
Meyer D; Schmid HP; Engeler DS
Wien Med Wochenschr; 2007; 157(7-8):162-9. PubMed ID: 17492413
[TBL] [Abstract][Full Text] [Related]
10. [BCG and radiotherapy: the compatibility of 2 conservative treatments for cancer of the urinary bladder].
Sánchez-Martín FM; Palou Redorta J; Regalado Pareja R; Rubio Briones J; Villavicencio Mavric H; Vicente Rodríguez J
Arch Esp Urol; 1999 Sep; 52(7):749-58. PubMed ID: 10540765
[TBL] [Abstract][Full Text] [Related]
11. T1 and T2 bladder cancer: selecting optimal therapy.
Soloway MS
Eur Urol; 1998; 33 Suppl 4():16-7. PubMed ID: 9615202
[No Abstract] [Full Text] [Related]
12. T1G3 bladder cancer--the case for TUR and BCG.
Miller K
Front Radiat Ther Oncol; 2002; 36():147-50. PubMed ID: 11842744
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
